首页> 美国卫生研究院文献>other >Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review
【2h】

Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review

机译:基于纳米技术的黑素瘤抗肿瘤治疗药物递送系统:综述。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Melanoma (MEL) is a less common type of skin cancer, but it is more aggressive with a high mortality rate. The World Cancer Research Fund International (GLOBOCAN 2012) estimates that there were 230,000 new cases of MEL in the world in 2012. Conventional MEL treatment includes surgery and chemotherapy, but many of the chemotherapeutic agents used present undesirable properties. Drug delivery systems are an alternative strategy by which to carry antineoplastic agents. Encapsulated drugs are advantageous due to such properties as high stability, better bioavailability, controlled drug release, a long blood circulation time, selective organ or tissue distribution, a lower total required dose, and minimal toxic side effects. This review of scientific research supports applying a nanotechnology-based drug delivery system for MEL therapy.
机译:黑色素瘤(MEL)是一种较不常见的皮肤癌,但它更具侵略性,死亡率高。国际世界癌症研究基金会(GLOBOCAN 2012)估计,2012年世界上有23万例新的MEL病例。常规的MEL治疗包括手术和化学疗法,但是使用的许多化学治疗剂表现出不良的特性。药物递送系统是携带抗肿瘤药的替代策略。封装的药物由于诸如高稳定性,更好的生物利用度,受控的药物释放,较长的血液循环时间,选择性的器官或组织分布,较低的总所需剂量和最小的毒副作用等特性而具有优势。这项科学研究综述支持将基于纳米技术的药物输送系统应用于MEL治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号